At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVAX Novavax
Market Closed 12-20 16:00:00 EST
8.70
+0.02
+0.23%
盘后8.74
+0.04+0.46%
19:59 EST
High8.89
Low8.37
Vol6.09M
Open8.59
D1 Closing8.68
Amplitude5.96%
Mkt Cap1.39B
Tradable Cap1.25B
Total Shares160.18M
T/O52.90M
T/O Rate4.25%
Tradable Shares143.36M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Novavax’s Strategic Partnerships and Pipeline Developments Drive Buy Rating with Promising Long-term Growth Potential
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.